Jilin Province Huinan Changlong Bio-pharmacy Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Hong Zhang
Chief executive officer
CN¥623.0k
Total compensation
| CEO salary percentage | 43.8% |
| CEO tenure | 35.2yrs |
| CEO ownership | 18.2% |
| Management average tenure | 17.2yrs |
| Board average tenure | 7.5yrs |
Recent management updates
Here's Why Shareholders May Consider Paying Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) CEO A Little More
May 21
It's Unlikely That Shareholders Will Increase Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) Compensation By Much This Year
Jun 05How Is Jilin Province Huinan Changlong Bio-pharmacy's (HKG:8049) CEO Paid Relative To Peers?
Nov 26Recent updates
Here's Why Shareholders May Consider Paying Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) CEO A Little More
May 21There May Be Reason For Hope In Jilin Province Huinan Changlong Bio-pharmacy's (HKG:8049) Disappointing Earnings
Apr 04With EPS Growth And More, Jilin Province Huinan Changlong Bio-pharmacy (HKG:8049) Makes An Interesting Case
Mar 26Investors Don't See Light At End Of Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) Tunnel
Dec 27With EPS Growth And More, Jilin Province Huinan Changlong Bio-pharmacy (HKG:8049) Makes An Interesting Case
Jul 12It's Unlikely That Shareholders Will Increase Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) Compensation By Much This Year
Jun 05How Is Jilin Province Huinan Changlong Bio-pharmacy's (HKG:8049) CEO Paid Relative To Peers?
Nov 26CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥172m |
| Mar 31 2024 | n/a | n/a | CN¥148m |
| Dec 31 2023 | CN¥623k | CN¥273k | CN¥148m |
| Sep 30 2023 | n/a | n/a | CN¥222m |
| Jun 30 2023 | n/a | n/a | CN¥197m |
| Mar 31 2023 | n/a | n/a | CN¥212m |
| Dec 31 2022 | CN¥539k | CN¥239k | CN¥194m |
| Sep 30 2022 | n/a | n/a | CN¥151m |
| Jun 30 2022 | n/a | n/a | CN¥172m |
| Mar 31 2022 | n/a | n/a | CN¥157m |
| Dec 31 2021 | CN¥520k | CN¥272k | CN¥143m |
| Sep 30 2021 | n/a | n/a | CN¥141m |
| Jun 30 2021 | n/a | n/a | CN¥124m |
| Mar 31 2021 | n/a | n/a | CN¥133m |
| Dec 31 2020 | CN¥515k | CN¥267k | CN¥127m |
| Sep 30 2020 | n/a | n/a | CN¥140m |
| Jun 30 2020 | n/a | n/a | CN¥143m |
| Mar 31 2020 | n/a | n/a | CN¥143m |
| Dec 31 2019 | CN¥526k | CN¥278k | CN¥145m |
| Sep 30 2019 | n/a | n/a | CN¥157m |
| Jun 30 2019 | n/a | n/a | CN¥159m |
| Mar 31 2019 | n/a | n/a | CN¥158m |
| Dec 31 2018 | CN¥1m | CN¥290k | CN¥161m |
| Sep 30 2018 | n/a | n/a | CN¥144m |
| Jun 30 2018 | n/a | n/a | CN¥144m |
| Mar 31 2018 | n/a | n/a | CN¥145m |
| Dec 31 2017 | CN¥506k | CN¥307k | CN¥144m |
Compensation vs Market: Hong's total compensation ($USD85.39K) is below average for companies of similar size in the Hong Kong market ($USD231.13K).
Compensation vs Earnings: Hong's compensation has been consistent with company performance over the past year.
CEO
Hong Zhang (69 yo)
35.2yrs
Tenure
CN¥623,000
Compensation
Mr. Hong Zhang serves as the Chief Executive Officer and Compliance Officer at Jilin Province Huinan Changlong Bio-pharmacy Co. Ltd. and has been its Executive Chairman since October 1989. Mr. Zhang is res...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | no data | CN¥623.00k | 18.19% HK$ 141.7m | |
| CFO & Executive Director | 17.8yrs | CN¥439.00k | no data | |
| Deputy Technical GM & Executive Director | no data | CN¥261.00k | 0.93% HK$ 7.3m | |
| Deputy Sales Director & Executive Director | no data | CN¥182.00k | 0.16% HK$ 1.3m | |
| GM & Executive Director | 34yrs | CN¥478.00k | 7.55% HK$ 58.8m | |
| Executive GM & Executive Director | 6.9yrs | CN¥400.00k | no data | |
| Company Secretary | 16.7yrs | no data | no data |
17.2yrs
Average Tenure
57yo
Average Age
Experienced Management: 8049's management team is seasoned and experienced (17.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 35.2yrs | CN¥623.00k | 18.19% HK$ 141.7m | |
| CFO & Executive Director | 17.8yrs | CN¥439.00k | no data | |
| Deputy Technical GM & Executive Director | 6.5yrs | CN¥261.00k | 0.93% HK$ 7.3m | |
| Deputy Sales Director & Executive Director | 17.3yrs | CN¥182.00k | 0.16% HK$ 1.3m | |
| GM & Executive Director | 34yrs | CN¥478.00k | 7.55% HK$ 58.8m | |
| Executive GM & Executive Director | 6.5yrs | CN¥400.00k | no data | |
| Independent Non-Executive Director | 9.5yrs | CN¥10.00k | no data | |
| Supervisor | 8.6yrs | no data | no data | |
| Independent Non-Executive Director | 6.5yrs | CN¥72.00k | no data | |
| Supervisor | 6.5yrs | no data | no data | |
| Supervisor | 6.5yrs | no data | no data | |
| Independent Non-Executive Director | 3.3yrs | CN¥10.00k | no data |
7.5yrs
Average Tenure
55yo
Average Age
Experienced Board: 8049's board of directors are considered experienced (7.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 11:34 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jilin Province Huinan Changlong Bio-pharmacy Company Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ssu-Han Fu | Jih Sun Securities Investment Consulting Co., Ltd. |